drugset / Trial / NCT02295722
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Objective of study: To evaluate the safety and efficacy of infusional gemcitabine prior to HDM (high-dose melphalan) as HDCT (High Dose Chemotherapy) followed by autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Timeline
- Start
- 2015-04
- Primary completion
- 2023-02
- Completion
- 2023-02
Outcome
Outcome not reported
Stopped (Enrollment): “It did not show a significant benefit to justify completing the full target accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1.5 g | — |
| Subject | Gemcitabine | Small molecule | 2 g | — |
| Subject | Gemcitabine | Small molecule | 2.5 g | — |
| Subject | Melphalan | Small molecule | 200 mg/m2 | Intravenous |